Monoclonal antibody therapy for hematologic malignancies: Introduction

Seminars in Oncology

Volumn 30, Issue 4, 2003, Pages 421-423

  Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; GEMTUZUMAB OZOGAMICIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; BLOOD DISEASE; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0042737469     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00344-0     Document Type: Article

References (5)

1. Nadler LM, Stashenko P, Hardy R, et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147-3154, 1980
2. Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517-522, 1982
3. Miller RA, Maloney DG, McKillop J, et al: In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58:78-86, 1981
4. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507-2513, 2003
5. Johnson AJ, Mone AP, Abhyankar V, et al. Advances in the therapy of chronic lymphocytic leukemia. Curr Opin Hematol 10:297-305, 2003